573 related articles for article (PubMed ID: 18931551)
1. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
2. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin cell-adhesion molecule expression as a diagnostic adjunct in urothelial cytology.
Ross JS; Cheung C; Sheehan C; del Rosario AD; Bui HX; Fisher HA
Diagn Cytopathol; 1996 Jun; 14(4):310-5. PubMed ID: 8725130
[TBL] [Abstract][Full Text] [Related]
4. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
5. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
[TBL] [Abstract][Full Text] [Related]
7. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
8. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
9. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma.
Rao J; Seligson D; Visapaa H; Horvath S; Eeva M; Michel K; Pantuck A; Belldegrun A; Palotie A
Cancer; 2002 Sep; 95(6):1247-57. PubMed ID: 12216092
[TBL] [Abstract][Full Text] [Related]
10. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
11. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies.
Bryan RT; Atherfold PA; Yeo Y; Jones LJ; Harrison RF; Wallace DM; Jankowski JA
J Pathol; 2008 Jun; 215(2):184-94. PubMed ID: 18393367
[TBL] [Abstract][Full Text] [Related]
12. [Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof].
Yu L; Chen XJ; Shi PQ; Ding Q; Sun CH; Liu GB; Shi DM; Huang YG
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(38):2683-4. PubMed ID: 19080686
[TBL] [Abstract][Full Text] [Related]
13. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
14. Telomerase activity in patients with transitional cell carcinoma: a preliminary study.
Rahat MA; Lahat N; Gazawi H; Resnick MB; Sova Y; Ben-Ari G; Cohen M; Stein A
Cancer; 1999 Feb; 85(4):919-24. PubMed ID: 10091771
[TBL] [Abstract][Full Text] [Related]
15. p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance.
Hu X; Ruan Y; Cheng F; Yu W; Zhang X; Larré S
Int J Urol; 2011 Sep; 18(9):630-7. PubMed ID: 21672035
[TBL] [Abstract][Full Text] [Related]
16. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
[TBL] [Abstract][Full Text] [Related]
17. [E-CD expression and its clinical significance in human bladder carcinoma].
Hao Y; Zhao C; Li X; Teng M
Zhonghua Wai Ke Za Zhi; 1999 Aug; 37(8):459-61. PubMed ID: 11829888
[TBL] [Abstract][Full Text] [Related]
18. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
19. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
Ro JY; Shen SS; Lee HI; Hong EK; Lee YH; Cho NH; Jung SJ; Choi YJ; Ayala AG
Am J Surg Pathol; 2008 May; 32(5):752-7. PubMed ID: 18379419
[TBL] [Abstract][Full Text] [Related]
20. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.
Bringuier PP; Umbas R; Schaafsma HE; Karthaus HF; Debruyne FM; Schalken JA
Cancer Res; 1993 Jul; 53(14):3241-5. PubMed ID: 8324734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
